ATL1103 Successfully Progresses Towards Phase II Clinical Trial
ATL1103 Phase I trial successfully meets primary endpoint – safe and well
tolerated
? Preliminary indication of drug activity shown with reduction of serum IGF-I
and other markers of drug activity
? Next step is a Phase II trial in patients with the growth disorder,
acromegaly
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.001(12.5%) |
Mkt cap ! $9.786M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 1.0¢ | 0.8¢ | $19.80K | 2.143M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1261758 | 0.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 6174345 | 9 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| PER (ASX) Chart |